Last reviewed · How we verify
Cozzar tablet
Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.
Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure.
At a glance
| Generic name | Cozzar tablet |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors on vascular smooth muscle and other tissues. By preventing angiotensin II from binding to these receptors, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced sodium retention. This mechanism makes it effective for hypertension management and renal protection in diabetic patients.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Key clinical trials
- Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions (PHASE1)
- The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cozzar tablet CI brief — competitive landscape report
- Cozzar tablet updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI